N-Acetyl Selank Amidate vs Semax
Comparison of N-Acetyl Selank Amidate (Very Low evidence) and Semax (Moderate evidence).
Last updated: February 12, 2026
N-Acetyl Selank Amidate
Semax
Overview
N-Acetyl Selank Amidate and Semax are both studied in the peptide research space.
N-Acetyl Selank Amidate: A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability.
Semax: A synthetic heptapeptide analogue of ACTH(4-7) with a C-terminal Pro-Gly-Pro extension, developed by Russian researchers and approved in Russia since ~1997 for stroke, cognitive impairment, and optic nerve disorders.
Evidence Comparison
| Aspect | N-Acetyl Selank Amidate | Semax |
|---|---|---|
| Evidence Level | Very Low | Moderate |
| Human Studies | 0 | 8 |
| Preclinical Studies | 2 | 24 |
| Total Sources | 2 | 32 |
Key Differences
| Aspect | N-Acetyl Selank Amidate | Semax |
|---|---|---|
| Category | Cognitive | Cognitive |
| Evidence Strength | Very Low | Moderate |
| Total Sources | 2 | 32 |
| Human Studies | 0 | 8 |
Summary
- N-Acetyl Selank Amidate: Very Low evidence with 2 total sources (0 human)
- Semax: Moderate evidence with 32 total sources (8 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.